Skip to main content
Terug
ARSUF logo

Fagron N.V.

Datakwaliteit: 100%
ARSUF
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 27,00
€ 0,00 (0,00%)
Marktkapitalisatie: 1,98B
Dagbereik
€ 27,00 € 27,00
52-Weeksbereik
€ 20,03 € 27,00
Volume
2.500
50D / 200D Gem.
€ 26,41 / € 24,68
Vorige Slotkoers
€ 27,00

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 21,7 0,4
P/B 3,6 2,9
ROE % 17,3 3,7
Net Margin % 9,6 3,9
Rev Growth 5Y % 13,5 10,0
D/E 0,9 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2029 € 2,41
€ 2,32 – € 2,49
 1,5 B 1
FY2028 € 1,85
€ 1,78 – € 1,91
 1,3 B 1
FY2027 € 1,60
€ 1,54 – € 1,66
 1,2 B 1

Belangrijkste Punten

Revenue grew 13,49% annually over 5 years — strong growth
ROE of 17,29% — decent returns on equity
Generating 112,98M in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 4,33%
Cash machine — converts 124,18% of earnings into free cash flow
Capital efficient — spends only 1,60% of revenue on capex

Groei

Revenue Growth (5Y)
13,49%
Revenue (1Y)9,16%
Earnings (1Y)12,95%
FCF Growth (3Y)14,51%

Kwaliteit

Return on Equity
17,29%
ROIC10,30%
Net Margin9,56%
Op. Margin15,36%

Veiligheid

Debt / Equity
0,93
Current Ratio2,11
Interest Coverage4,47

Waardering

P/E Ratio
21,73
P/B Ratio3,59
EV/EBITDA15,77
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 9,16% Revenue Growth (3Y) 11,69%
Earnings Growth (1Y) 12,95% Earnings Growth (3Y) 13,57%
Revenue Growth (5Y) 13,49% Earnings Growth (5Y) 10,51%
Profitability
Revenue (TTM) 951,81M Net Income (TTM) 90,99M
ROE 17,29% ROA 7,32%
Gross Margin 15,25% Operating Margin 15,36%
Net Margin 9,56% Free Cash Flow (TTM) 112,98M
ROIC 10,30% FCF Growth (3Y) 14,51%
Safety
Debt / Equity 0,93 Current Ratio 2,11
Interest Coverage 4,47 Dividend Yield 0,02%
Valuation
P/E Ratio 21,73 P/B Ratio 3,59
P/S Ratio 2,08 PEG Ratio 1,26
EV/EBITDA 15,77 Dividend Yield 0,02%
Market Cap 1,98B Enterprise Value 2,31B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 951,81M 871,96M 762,99M 683,88M 573,81M
Net Income 90,99M 80,55M 70,55M 69,61M 61,00M
EPS (Diluted) 1,24 1,10 0,97 0,96 0,84
Gross Profit 145,13M 395,68M 332,61M 286,17M 247,50M
Operating Income 146,16M 130,70M 108,63M 97,91M 87,44M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,24B 1,08B 1,01B 971,01M 800,42M
Total Liabilities 686,62M 578,16M 539,33M 562,38M 474,96M
Shareholders' Equity 551,40M 501,35M 463,75M 402,66M 320,11M
Total Debt 512,59M 385,70M 366,74M 399,38M 335,59M
Cash & Equivalents 184,83M 115,04M 133,01M 125,34M 70,65M
Current Assets 462,67M 362,56M 335,90M 318,01M 233,71M
Current Liabilities 218,90M 194,71M 175,26M 171,01M 145,06M

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#782 of 1024
32
Custom Balanced Risk
#142 of 148
26

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Balanced Risk
Mar 24, 2026